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Abstract
Background: Recently, several publications have investigated a possible drug interaction between clopidogrel and
proton pump inhibitors (PPIs), and regulatory agencies have issued warnings despite discordant study results. In an
attempt to clarify the situation, we performed a systematic review with a critical analysis of study methodologies to
determine whether varying study quality (that is, bias) could explain the discordant results.
Methods: A systematic review of all studies reporting clinical outcomes was performed using an electronic
literature search of the MEDLINE and EMBASE databases, abstracts from the major cardiology conferences and a
hand-search of bibliographies from identified articles. Each study was evaluated for its risk of bias according to a
prespecified quality measure scale.
Results: A total of 18 studies were identified. Ten of 13 studies judged to be of low scientific quality reported a
statistically positive interaction between clopidogrel and the general class of PPIs, and each concluded this was
likely a clinically meaningful effect. None of the five studies judged to be of moderate or high quality reported a
statistically significant association. Multiple sources of heterogeneity (that is, different populations, outcomes
assessed, drug exposure methods and study quality) prevented a formal quantitative analysis of all studies. An
increased risk of bias was observed in the positive studies, resulting in an inverse correlation between study quality
and a reported statistically positive interaction (10/13 versus 0/5; P = p = 0.007). There was also no clinical
evidence for a positive interaction according to specific PPIs.
Conclusion: The observed association between clopidogrel and PPIs is found uniquely in studies judged to be of
low quality and with an increased risk of bias. High-quality evidence supporting a clinically significant clopidogrel/
PPI interaction is presently lacking.
Background
Clopidogrel is a widely prescribed thienopyridine for the
prevention of atherothrombotic complications following
acute coronary syndromes (ACS) or percutaneous cor-
onary interventions (PCIs) [1]. Clopidogrel is a prodrug
that has no intrinsic antiplatelet activity without activa-
tion by hepatic metabolism through the cytochrome
P450 (CYP) system [2]. Multiple CYP enzymes have
been implicated in this process, but recently the
CYP2C19 enzyme has assumed predominance as it is
involved in both sequential oxidative steps [3]. The pos-
sibility of drug interactions limiting clopidogrel’s efficacy
was raised several years following in vitro statin and clo-
pidogrel studies, but without definitive clinical
confirmation of increased adverse outcomes [4-6].
Recently, mechanistic in vitro studies have suggested
that proton pump inhibitors (PPIs) may diminish clopi-
dogrel’s clinical efficacy via CYP2C19 competitive inhi-
bition [7-10]. Consistent with these in vitro
observations, several clinical studies have shown higher
cardiovascular events in clopidogrel patients exposed to
PPIs compared to those not exposed [11,12], leading the
Food and Drug Administration (FDA) [13] and the Eur-
o p e a nM e d i c i n e sA g e n c y[ 1 4 ]t oi s s u ep u b l i ca l e r t s
recommending the avoidance of prescribing PPIs in
patients who also take clopidogrel. However, as the stu-
dies have largely been nonexperimental, the possibility
of a spurious association due to bias needs to be atten-
tively considered.
This is a clinically important question as many cardiac
patients are also at high risk of gastrointestinal (GI)
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scribed drugs), and PPIs may substantially mitigate this
risk [15]. Previous reviews of this interaction question
have appeared [16-20], but they have not (1) been sys-
tematic, (2) provided a critical analysis of methodologi-
cal issues or (3) integrated these safety concerns with
prior knowledge of clopidogrel’s time frame of action.
The present review addresses these issues by performing
a systematic and critical analysis of all clinical studies of
this putative interaction.
Methods
We reviewed the MEDLINE and EMBASE electronic
databases from January 1, 2005, to October 7, 2010,
without any language restriction, combining search
terms for clopidogrel ("clopidogrel” OR “Plavix” OR
“thienopyridine”), PPIs ("PPI” OR “ omeprazole” OR
“lansoprazole” OR “pantoprazole” OR “esomeprazole”
OR “rabeprazole”) with those for cardiovascular out-
comes ("mortality” OR “cardiovascular disease” OR
“heart disease” OR “CAD” OR “MI” OR “UA” OR “cor-
onary angiography” OR “coronary restenosis” OR “PCI”
OR “stroke”) and drug interaction ("interaction” OR “
inhibition” OR “ CYP2C19”). References of relevant
identified articles were hand-searched for additional stu-
dies. Abstracts from medical organization conferences
(American Heart Association, American College of Car-
diology, European Society of Cardiology and Transcath-
eter Cardiovascular Therapeutics) were manually
searched from 2005. Ap r i o r iit was decided that only
articles reporting clinical outcomes would be retained.
Mechanistic in vitro studies measuring platelet aggrega-
tion were therefore excluded. Two investigators inde-
pendently reviewed articles for inclusion and study
quality. Both reviewers examined the methodology com-
ponent independently of the study results, but given the
publicity surrounding the individual studies it was
i m p o s s i b l et oe n s u r et h a tt h er e v i e w e r sw e r et o t a l l y
blinded to the outcomes. It was planned to resolve dis-
agreements by consensus, but there was perfect agree-
ment between the investigators on their initial
assessments. This systematic review was performed
according to the PRISMA guidelines (see online Addi-
tional file 1).
Overall study quality was defined as high for well-per-
formed randomized clinical trials (RCTs) as they exhibit
the best internal validity. Observational studies are con-
sidered of lower quality as they have less internal valid-
ity due to numerous potential biases and consequently
could attain a maximum moderate quality score. By fol-
lowing published guidelines to improve the reporting of
observational studies [21] and specifically to mitigate
against potential biases [22], we qualitatively evaluated
all the observational studies for their propensity for the
most common and important biases (selection, con-
founding and misclassification), thereby allowing their
final classification into moderate- or low-quality levels.
Overall observational study quality was judged to be
moderate if the propensity for bias was low and specific
methods to minimize bias were employed (explicit con-
sideration of the time dependency of drug exposure and
appropriate clinical outcome assessment to minimize
misclassification, multiple methods to assess confound-
ing and multivariate sensitivity analyses to test the inde-
pendence and robustness of their results). Alternatively,
studies were judged to be at moderate risk for bias and
hence a low quality score.
The quality score of unpublished studies was systema-
tically reduced by one grade owing to the absence of
formal peer review. Isolated abstracts were considered
to be of low quality as there are insufficient details to
fully evaluate these reports. Finally, whenever possible,
an external quality measure that compared survival
curves from the clopidogrel efficacy randomized trials to
the observational hazard ratios was performed to check
for consistency in the etiologically relevant time
windows.
Since study heterogeneity existed with respect to
research methods, quality, study populations and health
care systems, it was decided ap r i o r ithat quantitative
data pooling was inappropriate.
Results
Our literature search found 54 publications, and 18 of
these studies [11,12,23-38] fulfilled our inclusion criteria
(see Figure 1). One study was experimental with random
PPI allocation [25], while the others were nonexperi-
mental. Study details are presented in Table 1. Two stu-
dies [12,36] with an otherwise low propensity for bias
considered a primary endpoint of only nonfatal myocar-
dial infarction (MI), ignoring fatal myocardial infarction,
which has been a recurrent component of the composite
measure of clopidogrel efficacy. Although an increased
risk with the clopidogrel-PPI combination for nonfatal
myocardial infarction was observed in both studies,
mortality was actually lower in the PPI-exposed group
i no n es t u d y[ 1 2 ]a n dw a sn o tr e p o r t e di nt h eo t h e r
[36], such that the more logical and standard combined
endpoint of cardiovascular death and nonfatal MI could
not be reliably evaluated. The lack of justification for
their primary outcome and lack of sensitivity analyses
regarding potential different adverse outcomes explains
the lower assigned quality ratings for these two studies.
Among the full published studies judged to be methodo-
logically weak, several potential biases (selection, residual
confounding, immortal time and interpretative) were
noted. Ten of 13 studies judged to be of low quality
reported a statistically significant association for a harmful
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ate-quality studies found an association (P = 0.007).
Each individual study evaluated a combined exposure
to any PPI for the assessment of their primary endpoint,
with the exception of the experimental study [25], which
was restricted to omeprazole. One study [12] did report
a difference between pantoprazole and nonpantoprazole
PPIs in their association with adverse clinical outcomes,
but the corrected proper statistical analysis actually
revealed no difference [39]. No other study demon-
strated a clinically significant difference in clinical out-
comes among the different PPIs.
0 additional studies 
identified from 
references of the 
identified studies 
Abstracts from 
Cardiology 
Meetings 
N=9 
MEDLINE 
EMBASE 
N= 44 
53 titles identified in literature search 
47 potentially relevant titles, retrieved as 
full-texts and abstracts 
6 titles/abstracts excluded upon inspection 
22 potentially relevant titles: 10 
retrieved as full-texts, 11 as 
abstracts and 1 as a letter 
25 full text articles and abstracts excluded 
upon visual inspection (not relevant) 
4 abstracts excluded: 
-  Impossible to interpret (despite 
contacting authors) (n=1) 
-  Duplicate publications (n=3) 
 
18 articles included in the systematic 
review 
Figure 1 Flow diagram of selection process of studies included in the systematic review.
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Page 3 of 9Table 1 Study detailsa
Study Population
(special
conditions)
PPIs
studied
Propensity
for bias*
Procedures
to
minimize
bias**
Study
quality***
Primary
outcome/
Results
(all PPIs
combined)
Secondary analyses
according to specific
PPIs
Authors’ conclusions
about clopidogrel-PPI
interaction
Ho et al. [11] 8,205 ACS
(VA
patients)
L, O, P,
R
Moderate Yes Low 3-year mortality
or ACS
OR: 1.25; 95% CI:
1.11-1.41
O = OR: 1.24; 95% CI:
1.08-1.41
R = OR, 2.83; 95% CI:
1.96-4.09
LN R
PN R
“Concomitant use after
hospital discharge for
ACS was associated
with increased risk of
adverse outcomes.”
Juurlink et al.
[12]
13,636 ACS
(age ≥66)
L, O, P,
R
Moderate Yes Low 90-day nonfatal
MI
OR: 1.27; 95% CI:
1.03-1.57
P = OR 1.02, 95% CI
0.70-1.47
Non P = OR 1.40 (1.10-
1.77)
“Concomitant therapy
with PPIs other than
pantoprazole was
associated with loss of
beneficial effects of
clopidogrel.”
Aubert et al.
[23]
14,383 PCI NR Uncertain Uncertain Low 1-year combined
stroke, MI,
angina or CABG
OR:1.79; 95% CI
1.62-1.97
NR “The drug interaction
between PPIs and
clopidogrel may result
in serious adverse
outcomes within one
year of therapy
initiation.”
Banerjee et
al. [24]
534 PCI NR Uncertain Uncertain Low Mortality, MI,
repeat
revascularization
and stroke
OR 1.54 no CI P
< 0.006
(557-615 days)
NR “PPI(s) with clopidogrel
is associated with an
increased risk.”
Bhatt et al.
[25]
3,267 ACS
PCI
O Low Yes High 130-day CD,
nonfatal MI,
revascularization
or ischemic
stroke
HR: 1.02; 95% CI
= 0.70-1.51
Only O studied “No apparent
cardiovascular
interaction between
clopidogrel and
omeprazole”
Dunn et al.
[26]
1,053 PCI NR Uncertain No Low 1-year death, MI
or stroke
OR: 1.63; 95% CI,
1.02-2.62
NR “PPI use was
associated with an
increased
cardiovascular risk.”
Gaspar et al.
[27]
922 ACS O, L, R Uncertain Uncertain Low 6-month death,
MI or UA
8.8% vs. 8.4%, P
=N S
NR “Was not associated
with a worse prognosis
in patients with ACS”
Gupta et al.
[28]
315 PCI
(VA
patients)
L, O, R Moderate No Low 4-year death, MI
or TVF
OR: 1.95; 95% CI:
1.09-3.49
NR “PPIs may attenuate
clopidogrel’s beneficial
antiplatelet effect.”
Huang et al.
[29]
3,278 PCI
(Taiwan)
NR Moderate No Low 5-year all-cause
mortality
HR: 1.65; 95% CI,
1.35-2.01
NR “Concomitant use
should be done with
care to avoid adverse
outcomes.”
O’Donoghue
et al. [30]
6,795 ACS
(age ≥60)
E, L, O,
P, R
Low Yes Moderate 1-year CD, MI or
stroke
OR: 0.94; 95% CI:
0.80-1.11
No specific data reported
“Regardless of PPI type
(including omeprazole
alone or the exclusion of
pantoprazole), no
independent association
existed”
“No clinically relevant
adverse cardiovascular
interaction between
clopidogrel and PPIs.”
Pezalla et al.
[31]
1,010 ACS
(age <65)
NR Uncertain No Low 1-year adjusted
MI
OR 4.3; 95% CI
2.2-8.4
#
NR “Evidence is pointing
toward a potentially
significant interaction.”
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Our systematic review identified 18 clinical studies of a
clopidogrel-PPI interaction, with the majority (10)
reporting a statistically significant result. Multiple
sources of heterogeneity (different populations, out-
comes assessed, drug exposure methods and study qual-
ity) existed between the studies, preventing a formal
quantitative analysis of all studies. However, a stratified
analysis based on study quality demonstrated an inverse
correlation between study quality and a positive out-
come. Moreover, none of the 18 studies found a clini-
cally meaningful difference between the various PPIs.
Therefore, high-quality evidence supporting a clinically
significant clopidogrel-PPI interaction is presently lack-
ing. Consequently, while good prescribing patterns are
to be endorsed for all medications, recent edicts to
avoid PPIs in cardiac patients with a clinical indication
for their use seem poorly justified.
While our criteria for judging study quality are stan-
dardized and were applied a priori and independently of
the study results, their validity would be enhanced by
some empirical assessment. Certainly, these quality cri-
teria have face and content validity. In judging the pre-
sence of construct validity, it may be helpful to review
what is known about clopidogrel efficacy from high-
quality clinical trials. The Clopidogrel in Unstable
Table 1: Study detailsa (Continued)
Ramirez et al.
[32]
534 PCI NR Uncertain Uncertain Low 1-year mortality/
MI
OR NA
P = 0.32
NR “Concomitant use of
PPI’s did not result in
adverse cardiovascular
outcomes at one year.”
Rassen et al.
[33]
18,565 ACS
PCI
(age ≥65)
E, L, O,
P, R
Low Yes Moderate 180-day death
or MI
OR: 1.22; 95% CI:
0.99-1.51
O = RR 1.17; 95% CI:
0.68-2.01
P = RR 1.26; 95% CI:
0.93-1.71
“We did not observe
conclusive evidence of
a clopidogrel/PPI
interaction.”
Ray et al. [34] 20,596 ACS
PCI
(age ≥30)
E, L, O,
P, R
Low Yes Moderate 1-year MI, CD or
stroke
HR: 0.99; 95% CI,
0.82-1.19
E = HR 0.71; 95% CI 0.48-
1.06
L = HR 1.06; 95% CI 0.77-
1.45
O = HR 0.79;95% CI 0.54-
1.15
P = HR 1.08; 95% CI 0.88-
1.32
R = HR 0.54; 95% CI 0.30-
0.97
“Concurrent use of a
PPI was not associated
with a statistically
significant increased
risk for serious
cardiovascular disease.”
Sarafoff et al.
[35]
2,025 PCI NR Uncertain Uncertain Low 30-day stent
thrombosis
OR NR, P =
0.002
death OR NR, P
= 0.04
NR “A PPI is associated
with higher rates of
stent thrombosis and
an increased mortality.”
Stockl et al.
[36]
2,066 ACS
PCI
(age 18-84)
E, L, O,
P, R
Moderate Yes Low 1-year nonfatal
MI
HR: 1.93; 95% CI:
1.05-3.54
P = HR 2.18; 95% CI 0.88-
5.39
“Patients who received
clopidogrel plus a PPI
had a significantly
higher risk.”
Tsiaousis et
al. [37]
612 PCI NR Uncertain Uncertain Low 1-year death HR:
1.1; 95% CI: 0.7-
1.4
1-year MI HR:
1.0; 95% CI: 0.8-
1.3
NR “PPIs drug therapy
does not have any
impact on the
effectiveness.”
Charlot et al.
[38]
56,408 AMI E, L, O,
P
Low Yes Moderate 1-year death, MI,
stroke
HR: 0.98; 95% CI,
0.88-1.10
“No difference in risk
associated with the type
of PPI”
“No statistically
significant interaction
occurred between a
PPI and clopidogrel.”
aACS, acute coronary syndrome; AMI, acute myocardial infarction; AR, absolute risk; C, clopidogrel; CABG, coronary artery bypass graft; CD, cardiovascular death;
CI, confidence interval; HR, hazard ratio; MI, myocardial infarction; OHIP, Ontario health insurance program; OR, odds ratio; PCI, percutaneous coronary
intervention; PPI, proton pump inhibitor; TIA, transient ischemic attack; TVF, target vessel failure; TVR, target vessel revascularization; VA, Veterans Administration;
UA, unstable angina; NR, not reported; E, esomeprazole; L, lansoprazole; O, omeprazole; P, pantaprazole; R, rabeprazole.
*Biases considered are selection, confounding and misclassification; the probability of bias in the studies available as abstracts was deemed uncertain.
**Procedures to minimize bias include multiple sensitivity analyses for varying drug exposures, multiple methods for control of confounding and time-varying
analysis for misclassification.
***High study quality was reserved for RCTs. For observational studies, moderate study quality required low propensity for bias and specific efforts to minimize
bias. Otherwise, quality was assessed as low.
#Calculated by combining high- and low-dose PPI groups.
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was the seminal randomized trial [1] showing the bene-
fits of clopidogrel in acute coronary syndromes, namely,
a 1.9% absolute reduction in the primary endpoint of
cardiovascular death, nonfatal MI or stroke with clopi-
dogrel which was evident by 3 months with no or very
little additional advantage at later time points (see Fig-
ure 2). In a PCI trial [40], clopidogrel again was shown
to exhibit its beneficial results principally in the first 30-
90 days. A lack of long-term benefit in the non-acute
setting was confirmed in the randomized CHARISMA
trial [41], which showed no advantages in stable cardiac
or high-risk patients at any time over a 28-month fol-
low-up period. Contrast these results with those from
the observational studies of the putative drug interaction
attributing 9% [11] and 18% [28] absolute increases in
adverse outcomes to the inhibition of the protective
effects of clopidogrel. Another study [29] attributed a
greater than 15% absolute difference in all-cause mortal-
ity to this putative association. This represents a many-
fold larger effect than the observed clopidogrel benefits
in randomized trials. Moreover, in these studies, no sig-
nificant difference was seen between the clopidogrel-PPI
group and the clopidogrel-alone group within the thera-
peutically active 30-to 90-day window (see Figure 2).
The observed adverse effects attributed to the drug
interaction were therefore occurring at a time when clo-
pidogrel has not been shown to be therapeutically active.
It therefore seems likely that the observed differences
between PPI users and nonusers are unrelated to
                 
A B
D E
C
Figure 2 (A) Survival curves for the primary outcome (cardiovascular death, nonfatal myocardial infarction, or stroke) in randomized
trial [1]comparing clopidogrel to placebo following an acute coronary syndrome. (B) Survival curves for the primary outcome
(cardiovascular death, nonfatal myocardial infarction, or stroke) in randomized trial [39] comparing clopidogrel to placebo following PCI. (C)
Survival curves for the primary end point (cardiovascular death, myocardial infarction, or stroke) in randomized trial [40] comparing clopidogrel
to placebo in patients with clinically evident stable cardiovascular disease or multiple risk factors stable cardiac patients. (D) Survival curves for
primary outcome (mortality, non-fatal MI and target vessel revascularization) from an observational study [28] comparing PCI patients discharged
on clopidogrel plus proton pump inhibitor (PPI) and clopidogrel alone. (E) Survival curves for the primary end point (death acute coronary
syndrome) from an observational study [11] comparing ACS patients discharged on clopidogrel plus proton pump inhibitor (PPI) and clopidogrel
alone. The randomized trials following an ACS or PCI (Figures 2A and 2B) show that the benefit of clopidogrel is obtained early (see red arrow at
3 months) with no or little additional benefit accrued thereafter (see blue arrow at 9 months). The lack of long term benefit in stable patients
was confirmed in another randomized trial (Figure 2C). This is contrasted with the results of observational studies (Figures 2D and 2E) where
there appears to be no increased risk with PPIs in the short term and the differences arise in the long term where the benefits of clopidogrel
have not been demonstrated.
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confounding from unmeasured prognostic variables as
measured baseline prognostic factors were markedly dif-
ferent between the groups. Supporting this hypothesis, a
post hoc analysis of the CREDO study [26] showed a 2%
absolute increase in adverse cardiac events even among
placebo patients who were exposed to PPIs. Unfortu-
nately, the other observational studies have not pre-
sented survival functions, so a similar evaluation of the
biological plausibility and consistency of their results
cannot be made.
It bears repeating that the only high-quality rando-
mized trial permitting an unconfounded assessment of a
causal association [25] did not show any evidence of
harm. Moreover, it may be argued that post hoc analyses
of clinical trial data offer better internal validity than
other observational studies because of a greater homo-
geneity in the patient population, increased and higher-
quality baseline clinical data and better outcome valida-
tion, thereby potentially mitigating, but certainly not
eliminating, possible biases [22]. Our evaluation of the
present studies empirically confirmed this association,
with the post hoc clinical trial [30] receiving a higher
score by our independent criteria providing further
external support of our quality scale. Again, this higher-
quality study did not show evidence for the putative
interaction.
Our systematic review provides a reproducible, prespe-
cified and comprehensive review of the totality of the evi-
dence in the literature of a potential interaction between
clopidogrel and PPIs, thereby facilitating informed deci-
sion making. However, our systematic review may be cri-
ticized for our inability to ensure total blinding of
methodological assessment from outcomes. As with any
systematic review, we are also limited by the quality of
the original publications. While we found a paucity of
high-quality clinical evidence to support a clopidogrel-
PPI interaction either collectively or individually, the
power to find such an association is limited and does not
preclude the possibility that later high-quality studies
may appear to confirm this putative drug association.
The issue of adverse outcomes associated with conco-
mitant use of clopidogrel and PPIs has been assessed in
previous reviews [16-20], as well as by American and
European regulatory agencies [13,14], which concluded
that the interaction is clinically significant. However,
previous reviews have been dominated by studies with
surrogate laboratory endpoints, were not systematic in
identifying the clinical evidence, did not consider the
putative interaction effect as a function of our previous
knowledge of clopidogrel efficacy and did not provide a
critical analysis of the methodological issues of each
study. Lower-quality observational studies tend to over-
estimate effect size because of bias [42]. In the case of
regulatory agencies, the threshold to report putative
clinical adverse effects is naturally low in an effort to
protect public health. However, with the recent spate of
controversies regarding the cardiovascular safety of
approved drugs such as rofecoxib and rosiglitazone,
there is perhaps a strong desire for these agencies to
avoid appearing inactive and rather to be perceived as
proactive. Nevertheless, it is disconcerting that the
potential positive benefits of avoiding gastrointestinal
bleeds in high-risk patients appear to have been mini-
mized if not ignored and that regulatory decisions have
been made not on a systematic assessment of the clini-
cal evidence, but rather largely on surrogate laboratory
data and isolated clinical studies of questionable validity.
One regulatory agency [14] has targeted specific PPIs as
being culpable without a single valid clinical study to
support this claim. Correctly or not, the impression is
that the safety of the regulatory agencies from criticism
has become more important than the critical assessment
of public health safety.
Beyond our specific conclusion that the evidence for a
clinically meaningful clopidogrel-PPI interaction is poor,
o u rc r i t i c a la n a l y s i so ft h i sp otential drug interaction
leads to several general observations regarding pharma-
coepidemiological research and subsequent policy deci-
sions. First, selection bias or confounding by indication
remains a potential threat to all observational research
of both intended and unintended effects. Second, resi-
dual confounding is likely to be persistent when multi-
variate analysis is limited to data routinely collected
from purely administrative data sets lacking the neces-
sary clinical granularity. Post hoc analyses of randomized
trials are similarly subject to the same potential biases,
but the magnitude may be less owing to both a more
homogeneous source population (from the strict inclu-
sion and exclusion criteria, which favor the recruitment
of populations with only one major health issue), the
availability of more extensive baseline clinical data
(decreasing residual confounding) and more systematic
outcome assessment through adjudication (decreasing
misclassification or information bias), thereby allowing a
more rigorous assessment of the independent contribu-
tion of any putative association. Third, studies of surro-
gate endpoints (for example, platelet inhibition) may
provide interesting avenues for future outcomes
research, but these studies should not be used for clini-
cal and regulatory decision making. The perils of surro-
gate markers have been repeatedly demonstrated in
cardiovascular medicine, with specious examples ranging
from ventricular ectopy suppression to lowering of gly-
cosylated hemoglobin. Fourth, when possible, cohort
studies should present survival functions, which may
help in determining the reasonableness of conclusions
by ensuring that events occur within the etiologically
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Finally, the time-varying nature of drug exposure must
be meticulously tracked and sensitivity analyses must be
performed to assess the robustness of conclusions to
residual confounding or measurement error.
Readers should reasonably expect that the peer review
process provides some guidance and discussion about
potential biases in observational research. Too often
there is a tendency to explain discordant study results
not by considering biases, but by assuming that the
results are due to different populations, interventions or
outcomes [43,44]. In our opinion, the probability of
such effect modification is often small compared to the
probability of bias. While some biases are subtle, others
become more obvious with attentive reading and con-
sideration of the totality of the evidence. The need to
improve the reliability and value of medical research has
been well recognized by many groups [43-45], and sev-
eral guidelines have been published [21,22], including
those that pertain to observational research, but more
specific guidelines for designing and interpreting phar-
macoepidemiological studies may be helpful.
Conclusions
This systematic review of the putative drug interaction
between clopidogrel and PPIs identified 18 clinical studies.
Rigorous and extensive evaluation of the study methodolo-
gies demonstrated that the majority were of low quality,
and only these studies reported a positive association
between clopidogrel-PPI exposure and increased cardio-
vascular events. Supporting the notion that bias may be
responsible for a spurious association, the increase in car-
diovascular events attributed to this interaction appears to
be occurring within a therapeutic window when clopido-
grel has not been shown to be etiologically active. Conver-
sely, all studies assessed as high quality did not
demonstrate this association. No study was able to isolate
any individual PPI as being more prone to adverse cardiac
outcomes. Careful attention to the methodological details
of published studies is therefore mandatory to avoid reach-
ing questionable scientific conclusions. In light of this sys-
tematic review, and given the potential benefit of PPIs for
patients at high risk of gastrointestinal bleeding, regulatory
agencies may wish to reevaluate their recent edicts regard-
ing this putative interaction.
Additional material
Additional file 1: PRISMA Checklist. This file is recommended to be
included in all systematic review. The checklist enables the reader to
rapidly identify where the key elements required in a high-quality
systematic review are found.
Acknowledgements
This work did not benefit from any external funding. Dr Brophy is a funded
research scientist of Le Fonds de la Recherche en Santé du Québec.
Author details
1Federal University of Ceará School of Medicine, Fortaleza, Brazil.
2Department of Medicine, McGill University, Montreal, Quebec, Canada.
Authors’ contributions
JMB conceived the project. JMB and JPAL developed the protocol jointly
and independently abstracted the data. JMB did the statistical analysis. JMB
and JPAL jointly wrote all drafts and the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 23 September 2010 Accepted: 6 December 2010
Published: 6 December 2010
References
1. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, Clopidogrel in
Unstable Angina to Prevent Recurrent Events Trial Investigators: Effects of
clopidogrel in addition to aspirin in patients with acute coronary
syndromes without ST-segment elevation. N Engl J Med 2001,
345:494-502.
2. Savi P, Herbert JM, Pflieger AM, Dol F, Delebassee D, Combalbert J,
Defreyn G, Maffrand JP: Importance of hepatic metabolism in the
antiaggregating activity of the thienopyridine clopidogrel. Biochem
Pharmacol 1992, 44:527-532.
3. Steinhubl SR: Genotyping, clopidogrel metabolism, and the search for
the therapeutic window of thienopyridines. Circulation 2010, 121:481-483.
4. Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS, Tait AR,
Carville DG, Guyer KE, Bates ER: Atorvastatin reduces the ability of
clopidogrel to inhibit platelet aggregation: a new drug-drug interaction.
Circulation 2003, 107:32-37.
5. Martin PT, Denman R: Atorvastatin-clopidogrel interaction. Circulation
2003, 107:e223.
6. Mitsios JV, Papathanasiou AI, Rodis FI, Elisaf M, Goudevenos JA, Tselepis AD:
Atorvastatin does not affect the antiplatelet potency of clopidogrel
when it is administered concomitantly for 5 weeks in patients with
acute coronary syndromes. Circulation 2004, 109:1335-1338.
7. Cuisset T, Frere C, Quilici J, Poyet R, Gaborit B, Bali L, Brissy O, Morange PE,
Alessi MC, Bonnet JL: Comparison of omeprazole and pantoprazole
influence on a high 150-mg clopidogrel maintenance dose the PACA
(Proton Pump Inhibitors And Clopidogrel Association) prospective
randomized study. J Am Coll Cardiol 2009, 54:1149-1153.
8. Gilard M, Arnaud B, Cornily JC, Le GG, Lacut K, Le CG, Mansourati J,
Mottier D, Abgrall JF, Boschat J: Influence of omeprazole on the
antiplatelet action of clopidogrel associated with aspirin: the
randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin)
study. J Am Coll Cardiol 2008, 51:256-260.
9. Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B: Effects of
pantoprazole and esomeprazole on platelet inhibition by clopidogrel.
Am Heart J 2009, 157:148, e1-e5.
10. Small DS, Farid NA, Payne CD, Weerakkody GJ, Li YG, Brandt JT, Salazar DE,
Winters KJ: Effects of the proton pump inhibitor lansoprazole on the
pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.
J Clin Pharmacol 2008, 48:475-484.
11. Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, Rumsfeld JS:
Risk of adverse outcomes associated with concomitant use of
clopidogrel and proton pump inhibitors following acute coronary
syndrome. JAMA 2009, 301:937-944.
12. Juurlink DN, Gomes T, Ko DT, Szmitko PE, Austin PC, Tu JV, Henry DA,
Kopp A, Mamdani MM: A population-based study of the drug interaction
between proton pump inhibitors and clopidogrel. CMAJ 2009,
180:713-718.
13. Food and Drug Adminstration: Information for Healthcare Professionals:
Update to the labeling of Clopidogrel Bisulfate (marketed as Plavix) to
alert healthcare professionals about a drug interaction with omeprazole
Lima and Brophy BMC Medicine 2010, 8:81
http://www.biomedcentral.com/1741-7015/8/81
Page 8 of 9(marketed as Prilosec and Prilosec OTC). 2009 [http://www.fda.gov/Drugs/
DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/
DrugSafetyInformationforHeathcareProfessionals/ucm190787.htm], (accessed
Nov 1 2010).
14. European Medicines Agency: Interaction between clopidogrel and
proton-pump inhibitors. 2010 [http://www.ema.europa.eu/humandocs/
PDFs/EPAR/Plavix/17494810en.pdf], (accessed June 15 2010).
15. Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD,
Johnson DA, Mahaffey KW, Quigley EM, Harrington RA, Bates ER, Bridges CR,
Eisenberg MJ, Ferrari VA, Hlatky MA, Kaul S, Lindner JR, Moliterno DJ,
Mukherjee D, Schofield RS, Rosenson RS, Stein JH, Weitz HH, Wesley DJ:
ACCF/ACG/AHA 2008 expert consensus document on reducing the
gastrointestinal risks of antiplatelet therapy and NSAID use. Am J
Gastroenterol 2008, 103:2890-2907.
16. Chow CK, Moayyedi P, Devereaux PJ: Is it safe to use a proton pump
inhibitor with clopidogrel? Pol Arch Med Wewn 2009, 119:564-568.
17. Juhasz M, Herszenyi L, Tulassay Z: Current standings of the proton pump
inhibitor and clopidogrel co-therapy: review on an evolving field with
the eyes of the gastroenterologist. Digestion 2010, 81:10-15.
18. Juurlink DN: Proton pump inhibitors and clopidogrel: putting the
interaction in perspective. Circulation 2009, 120:2310-2312.
19. Norgard NB, Mathews KD, Wall GC: Drug-drug interaction between
clopidogrel and the proton pump inhibitors. Ann Pharmacother 2009,
43:1266-1274.
20. Zarowitz BJ: Clopidogrel: with or without a proton pump inhibitor?
Geriatr Nurs 2009, 30:188-192.
21. Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC,
Vandenbroucke JP, STROBE Initiative: The Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE) statement: guidelines
for reporting observational studies. Lancet 2007, 370:1453-1457.
22. Cox E, Martin BC, Van ST, Garbe E, Siebert U, Johnson ML: Good Research
Practices for Comparative Effectiveness Research: Approaches to
Mitigate Bias and Confounding in the Design of Nonrandomized Studies
of Treatment Effects Using Secondary Data Sources: The International
Society for Pharmacoeconomics and Outcomes Research Good Research
Practices for Retrospective Database Analysis Task Force Report-Part II.
Value Health 2009.
23. Aubert RE, Epstein RS, Teagarden JR, Xia F, Yao J, Desta Z, Skaar T,
Flockhart DA: Proton pump inhibitors effect on clopidogrel effectiveness:
the Clopidogrel Medco Outcomes Study. Circulation 2008, 118:S815.
24. Banerjee S, Varghese C, Weideman R, Weideman M, Little BB: Proton pump
inhibitors increase the risk of major adverse cardiovascular events in
post-PCI patients who are on clopidogrel (Abstract P653). Eur Heart J
2009, 30(Suppl):92.
25. Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, Shook TL,
Lapuerta P, Goldsmith MA, Laine L, Scirica BM, Murphy SA, Cannon CP:
Clopidogrel with or without omeprazole in coronary artery disease. N
Engl J Med 2010.
26. Dunn SP, Macaulay TE, Brennan DM, Campbell CL, Charnigo RJ, Smyth SS,
Berger PB, Steinhubl SR, Topol EJ: Baseline proton pump inhibitor use is
associated with increased cardiovascular events with and without the
use of clopidogrel in the CREDO Trial. Circulation 2008, 118:S815, (Abstract
3999).
27. Gaspar A, Ribeiro S, Naibas S, et al: Proton pump inhibitors in patients
treated with aspirin and clopidogrel (Abstract P2679). Eur Heart J 2009,
30(Suppl):444.
28. Gupta E, Bansal D, Sotos J, Olden K: Risk of adverse clinical outcomes with
concomitant use of clopidogrel and proton pump inhibitors following
percutaneous coronary intervention. Dig Dis Sci 2010, 55:1964-1968.
29. Huang CC, Chen YC, Leu HB, Chen TJ, Lin SJ, Chan WL, Chen JW: Risk of
adverse outcomes in Taiwan associated with concomitant use of
clopidogrel and proton pump inhibitors in patients who received
percutaneous coronary intervention. Am J Cardiol 2010, 105:1705-1709.
30. O’Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER,
Rozenman Y, Michelson AD, Hautvast RW, Ver Lee PN, Close SL, Shen L,
Mega JL, Sabatine MS, Wiviott SD: Pharmacodynamic effect and clinical
efficacy of clopidogrel and prasugrel with or without a proton-pump
inhibitor: an analysis of two randomised trials. Lancet 2009, 374:989-997.
31. Pezalla E, Day D, Pulliadath I: Initial assessment of clinical impact of a
drug interaction between clopidogrel and proton pump inhibitors. JA m
Coll Cardiol 2008, 52:1038-1039.
32. Ramirez JF, Selzer F, Chakaprani R, et al: Proton pump inhibitor and
clopidogrel combination is not associated with adverse clinical
outcomes after PCI: the NHLBI dynamic registry. J Am Coll Cardiol 2009,
53(Suppl 1):A27.
33. Rassen JA, Choudhry NK, Avorn J, Schneeweiss S: Cardiovascular outcomes
and mortality in patients using clopidogrel with proton pump inhibitors
after percutaneous coronary intervention or acute coronary syndrome.
Circulation 2009, 120:2322-2329.
34. Ray WA, Murray KT, Griffin MR, Chung CP, Smalley WE, Hall K, Daugherty JR,
Kaltenbach LA, Stein CM: Outcomes with concurrent use of clopidogrel
and proton-pump inhibitors: a cohort study. Ann Intern Med 2010,
152:337-345.
35. Sarafoff N, Sibbing D, Sonntag U, Schulz S, Schoemig A, Kastrati A: Higher
stent thrombosis rate after coronary stenting in patients on dual
antiplatelet treatment and concomitant treatment with proton pump
inhibitors (abstr). Eur Heart J 2009, 30(Suppl):150.
36. Stockl KM, Le L, Zakharyan A, Harada AS, Solow BK, Addiego JE, Ramsey S:
Risk of rehospitalization for patients using clopidogrel with a proton
pump inhibitor. Arch Intern Med 2010, 170:704-710.
37. Tsiaousis GZ, Zairis MN, Patsourakos N, et al: Oral proton pump inhibitors
and their impact on the effectiveness of dual anti-platelet therapy
during the first year after elective coronary stenting (abstr). J Am Coll
Cardiol 2009, 53(Suppl A):A335.
38. Charlot M, Ahlehoff O, Norgaard ML, Jorgensen CH, Sorensen R,
Abildstrom SZ, Hansen PR, Madsen JK, Kober L, Torp-Pedersen C,
Gislason G: Proton-pump inhibitors are associated with increased
cardiovascular risk independent of clopidogrel use: a nationwide cohort
study. Ann Intern Med 2010, 153:378-386.
39. Allen MJ, McLean-Veysey P: Interaction between clopidogrel and proton
pump inhibitors. CMAJ 2009, 180:1228-1229.
40. Steinhubl SR, Berger PB, Mann JT III, Fry ET, DeLago A, Wilmer C, Topol EJ:
Early and sustained dual oral antiplatelet therapy following
percutaneous coronary intervention: a randomized controlled trial. JAMA
2002, 288:2411-2420.
41. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P,
Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW,
Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA,
Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J,
Topol EJ, CHARISMA Investigators: Clopidogrel and aspirin versus aspirin
alone for the prevention of atherothrombotic events. N Engl J Med 2006,
354:1706-1717.
42. Suissa S: Immortal time bias in pharmaco-epidemiology. Am J Epidemiol
2008, 167:492-499.
43. Altman DG: The scandal of poor medical research. BMJ 1994, 308:283-284.
44. Anonymous: Editorial: Are medical journals getting better-or worse?
Lancet 2009, 374:950.
45. EQUATOR: [http://www.equator-network.org/home/], Accessed June 15,
2010.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1741-7015/8/81/prepub
doi:10.1186/1741-7015-8-81
Cite this article as: Lima and Brophy: The potential interaction between
clopidogrel and proton pump inhibitors: a systematic review. BMC
Medicine 2010 8:81.
Lima and Brophy BMC Medicine 2010, 8:81
http://www.biomedcentral.com/1741-7015/8/81
Page 9 of 9